NovoCure (NVCR) Revenue & Revenue Breakdown
NovoCure Revenue Highlights
Latest Revenue (Y)
$509.34M
Latest Revenue (Q)
$155.09M
Main Geography (Y)
UNITED STATES
NovoCure Revenue by Period
NovoCure Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $509.34M | -5.30% |
| 2022-12-31 | $537.84M | 0.53% |
| 2021-12-31 | $535.03M | 8.23% |
| 2020-12-31 | $494.37M | 40.72% |
| 2019-12-31 | $351.32M | 41.62% |
| 2018-12-31 | $248.07M | 40.13% |
| 2017-12-31 | $177.03M | 113.57% |
| 2016-12-31 | $82.89M | 150.52% |
| 2015-12-31 | $33.09M | 113.60% |
| 2014-12-31 | $15.49M | 49.53% |
| 2013-12-31 | $10.36M | - |
NovoCure generated $509.34M in revenue during NA 2023, up -5.30% compared to the previous quarter, and up 205.32% compared to the same period a year ago.
NovoCure Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $155.09M | 3.15% |
| 2024-06-30 | $150.36M | 8.56% |
| 2024-03-31 | $138.50M | 3.53% |
| 2023-12-31 | $133.78M | 5.08% |
| 2023-09-30 | $127.32M | 1.01% |
| 2023-06-30 | $126.05M | 3.17% |
| 2023-03-31 | $122.18M | -4.86% |
| 2022-12-31 | $128.43M | -1.96% |
| 2022-09-30 | $131.00M | -7.01% |
| 2022-06-30 | $140.87M | 2.41% |
| 2022-03-31 | $137.55M | 3.25% |
| 2021-12-31 | $133.21M | -0.29% |
| 2021-09-30 | $133.61M | 0.07% |
| 2021-06-30 | $133.52M | -0.87% |
| 2021-03-31 | $134.69M | -6.43% |
| 2020-12-31 | $143.95M | 8.51% |
| 2020-09-30 | $132.66M | 14.44% |
| 2020-06-30 | $115.92M | 13.84% |
| 2020-03-31 | $101.83M | 2.61% |
| 2019-12-31 | $99.23M | 7.79% |
| 2019-09-30 | $92.06M | 6.17% |
| 2019-06-30 | $86.71M | 18.28% |
| 2019-03-31 | $73.31M | 5.22% |
| 2018-12-31 | $69.67M | 7.59% |
| 2018-09-30 | $64.76M | 5.27% |
| 2018-06-30 | $61.51M | 18.01% |
| 2018-03-31 | $52.13M | -2.86% |
| 2017-12-31 | $53.66M | 7.09% |
| 2017-09-30 | $50.11M | 30.57% |
| 2017-06-30 | $38.38M | 10.02% |
| 2017-03-31 | $34.88M | 15.34% |
| 2016-12-31 | $30.24M | 39.53% |
| 2016-09-30 | $21.67M | 20.96% |
| 2016-06-30 | $17.92M | 37.28% |
| 2016-03-31 | $13.05M | 5.41% |
| 2015-12-31 | $12.38M | 38.31% |
| 2015-09-30 | $8.95M | 36.83% |
| 2015-06-30 | $6.54M | 25.63% |
| 2015-03-31 | $5.21M | 37.02% |
| 2014-12-31 | $3.80M | -13.10% |
| 2014-09-30 | $4.37M | - |
NovoCure generated $155.09M in revenue during Q3 2024, up 3.15% compared to the previous quarter, and up 123.04% compared to the same period a year ago.
NovoCure Revenue Breakdown
NovoCure Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| International Markets | $136.37M | - | - | - | - |
| JAPAN | $31.67M | $32.78M | $34.64M | $29.08M | $17.91M |
| UNITED STATES | $349.74M | $406.89M | $353.11M | $340.78M | $232.81M |
| CHINA | $23.22M | $21.33M | $22.77M | $12.59M | $5.25M |
| GERMANY | $60.21M | $46.12M | $93.94M | $93.26M | $86.56M |
| Other EMEA | - | $30.71M | $30.58M | - | - |
| EMEA | - | - | - | $18.65M | $8.78M |
NovoCure's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (58.17%), International Markets (22.68%), GERMANY (10.01%), JAPAN (5.27%), and CHINA (3.86%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHINA | $4.63M | $5.85M | $4.94M | $4.40M | $6.76M | $6.75M | $5.32M | $4.87M | $6.16M | $5.93M | $4.37M | $5.80M | $6.51M | $4.93M | $5.53M | $4.53M | $4.28M | $2.14M | $1.64M | $1.95M |
| JAPAN | $8.58M | $7.66M | $7.82M | $7.55M | $7.59M | $7.86M | $8.67M | $7.89M | $7.87M | $8.27M | $8.75M | $8.83M | $8.78M | $8.75M | $8.28M | $7.92M | $7.52M | $7.18M | $6.45M | $5.58M |
| UNITED STATES | $98.34M | $95.71M | $90.54M | $91.31M | $86.24M | $86.96M | $85.23M | $98.62M | $102.65M | $108.20M | $97.42M | $92.03M | $88.03M | $87.14M | $85.91M | $97.68M | $92.64M | $81.21M | $69.26M | $65.87M |
| FRANCE | $15.24M | $14.27M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GERMANY | $16.99M | $15.10M | $15.75M | $14.66M | $14.68M | $15.74M | $15.12M | $9.75M | $6.78M | $10.35M | $19.24M | $19.00M | $23.21M | $25.36M | $26.36M | $27.24M | $22.76M | $21.47M | $21.80M | $22.50M |
| International Markets | $52.13M | $48.80M | $43.02M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Others Countries | - | - | - | - | $12.05M | $8.74M | $7.85M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EMEA, Exculding Germany | - | - | - | - | - | - | - | - | $7.54M | $8.11M | $7.78M | $7.08M | $7.33M | $8.62M | $5.47M | $3.93M | $2.67M | - | - | - |
| EMEA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-60.73M |
NovoCure's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (50.20%), International Markets (26.61%), GERMANY (8.67%), FRANCE (7.78%), JAPAN (4.38%), and CHINA (2.36%).
NovoCure Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MASI | Masimo | $2.05B | $492.80M |
| PODD | Insulet | $1.70B | $488.50M |
| ITGR | Integer | $1.60B | $746.27M |
| GMED | Globus Medical | $1.57B | $629.69M |
| CNMD | CONMED | $1.24B | $316.70M |
| LIVN | LivaNova | $1.15B | $318.11M |
| PEN | Penumbra | $1.06B | $301.04M |
| SWAV | ShockWave Medical | $730.23M | $218.81M |
| INSP | Inspire Medical Systems | $624.80M | $195.88M |
| NVCR | NovoCure | $509.34M | $155.09M |
| NARI | Inari Medical | $493.63M | $153.39M |
| IRTC | iRhythm | $492.68M | $147.54M |
| INMD | InMode | $492.05M | $80.28M |
| TMDX | TransMedics Group | $241.62M | $-12.24M |
NVCR Revenue FAQ
What is NovoCure’s yearly revenue?
NovoCure's yearly revenue for 2023 was $509.34M, representing a decrease of -5.30% compared to 2022. The company's yearly revenue for 2022 was $537.84M, representing an increase of 0.53% compared to 2021. NVCR's yearly revenue for 2021 was $535.03M, representing an increase of 8.23% compared to 2020.
What is NovoCure’s quarterly revenue?
NovoCure's quarterly revenue for Q3 2024 was $155.1M, a 3.15% increase from the previous quarter (Q2 2024), and a 21.81% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $150.36M, a 8.56% increase from the previous quarter (Q1 2024), and a 19.28% increase year-over-year (Q2 2023). NVCR's quarterly revenue for Q1 2024 was $138.5M, a 3.53% increase from the previous quarter (Q4 2023), and a 13.36% increase year-over-year (Q1 2023).
What is NovoCure’s revenue growth rate?
NovoCure's revenue growth rate for the last 3 years (2021-2023) was -4.80%, and for the last 5 years (2019-2023) was 44.98%.